亿帆医药(002019.SZ)：子公司褪黑素颗粒境内生产药品注册上市许可申请获受理

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019.SZ) has received a production registration acceptance notice from the National Medical Products Administration for melatonin granules aimed at improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - The melatonin granules are specifically designed for children with neurodevelopmental disorders, indicating a targeted approach in the company's product development strategy [1] - As of the report date, the company has invested approximately 13.69 million yuan in the research and development of the melatonin granules raw materials and formulations [1]